|
Cytokinetics Inc.’s (NasdaqGM: CYTK - News) share price has moved into oversold territory with a stochastic value of 5.94. The Zacks Consensus Estimate on the company’s full-year earnings has climbed 40 cents over the past 3 months to 36 cents per share. Cytokinetics is a Zacks #1 Rank (“Strong Buy) company.
Sentiment : Buy Rating :
 (3 Ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
Messages in Topic
| Subject | Author | Rating | Time of Post (ET) | ||
|---|---|---|---|---|---|
|
interesting while the stock dropped!
|
the_real_wr...
Online Now
|
|
26-Oct-09 04:14 pm |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|